Abstract: CAR-T technology as a kind of immunotherapy, from the earlist generation of the first to the current fourth generation, its cytotoxic, anti-tumor immune effect greatly enhanced, but also challenged by safety issues. It shows a certain advantage in the therapy of hepatocellular carcinoma. It indicates that the era of precise individualized liver cancer treatment, immune therapy, especially CAR-T technology combined with surgery, radiotherapy and chemotherapy, local treatment and other comprehensive treatment will play a more powerful role.

Key words: Primary liver cancer, immune therapy, CAR-T therapy, Target antigen